PRESS RELEASE

AUGUST 2011

Acetylon Pharmaceuticals, Inc. Leases 10,000 RSF at Seaport Center, Boston, MA

Acetylon Pharmaceuticals, Inc. has leased 10,000 rentable square feet of lab and office space at Seaport Center, Boston, MA (www.seaportcenterboston.com), from The Beal Cos. and Rockpoint Group.  The space is a build to suit from gutted shell and has biology and chemistry labs, two BL-2 tissue culture labs, and office.

 Keith Coulter, President of McPherson Corporation/ATR Boston, represented Acetylon in the transaction.  Jones Lang Lasalle represented the landlord, and Steve Faber of Beal worked on behalf of the ownership.  Acetylon chose the site due to extremely attractive pricing, which was approximately 35-40% discount to Cambridge pricing for comparable space; a firm commitment to timing for delivery of the space by Beal as well as a demonstrated desire to win Acetylon’s tenancy and kick off biotech use in the building; and attractiveness of the location in recruiting and growing the company in a thriving and developing area of the city, as well as proximity to current research partners at Dana Farber Cancer Institute and Harvard Medical School.  The lease announcement follows on the heels of the Vertex Pharmaceuticals lease of 1.1 million square feet at Marina Park, the largest lease ever for the Boston market, and for a biotech use.

 Acetylon Pharmaceuticals Inc. (www.acetylon.com)is developing next-generation selective small molecule histone deacetylase (HDAC) inhibitors and other targeted drugs for the treatment of cancers as well as inflammatory, neurodegenerative, genetic and infectious diseases.  Selective HDAC inhibitors have the potential to reduce or eliminate the substantial side effects observed with current non-selective approaches while also realizing their extraordinary potential for enhanced therapeutic benefit through higher dosing, extended administration and reduction of combination drug toxicity. Selective HDAC inhibitors also have potential for improved therapeutic benefit in autoimmune and other inflammatory disorders, neurodegenerative diseases and certain genetic and infectious diseases.  Acetylon has raised over $40 million from public grants and investors, including New England Patriots owner Robert Kraft.

 McPherson Corporation (www.mcphersoncorp.com) has represented tenants and buyers exclusively for over 30 years, and is a founding member of the Alliance of Tenant Representatives (ATR – www.alltenrep.com); Mr. Coulter serves on the Board of Directors for ATR.